US Pharma MarketingBiopharma’s golden parachutes: 12 execs who took in the biggest M&A windfalls of $35M+
Twelve biopharma execs collected nearly $1B in golden parachutes from 2025–26 M&A deals, led by Cidara Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing…
A dozen biotech executives took home nearly $1 billion worth of exit packages from selling their companies, an Endpoints News analysis found.
The drug industry is undergoing a historic stretch of M&A, driven by many ...
Source: Endpoints News